Fostamatinib, acting on multiple targets and whose mechanism as an inhibitor of Syk has been confirmed, is now a first-line medication for Immune Thrombocytopenic Purpura (ITP). The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.